

Christopher J Hoimes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1906965/publications.pdf>

Version: 2024-02-01

55
papers

3,447
citations

236925

25
h-index

206112

48
g-index

57
all docs

57
docs citations

57
times ranked

6084
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
2	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
3	Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2500-2500.	1.6	17
4	Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4582-4582.	1.6	6
5	Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer. <i>Cancers</i> , 2021, 13, 417.	3.7	16
6	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
7	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
8	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	1.6	26
9	High-dose interleukin-2 therapy related adverse events and implications on imaging. , 2021, 27, 684-689.		3
10	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.1	74
11	Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. <i>Abdominal Radiology</i> , 2020, 45, 3028-3035.	2.1	9
12	Impact of performance status on treatment outcomes: A realâ€world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
13	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	1.6	450
14	Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 619-626.	0.9	4
15	Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients. <i>Emergency Radiology</i> , 2020, 27, 455-460.	1.8	10
16	Systemic Therapies for Melanoma Brain Metastases. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 346-355.	0.9	1
17	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
18	A phase 1 trial of SGNâ€CD70A in patients with CD70â€positive, metastatic renal cell carcinoma. <i>Cancer</i> , 2019, 125, 1124-1132.	4.1	41

#	ARTICLE	IF	CITATIONS
19	Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFN γ -Driven Antitumor Immunity. <i>Cancer Research</i> , 2019, 79, 5394-5406.	0.9	55
20	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 43-51.	7.0	177
21	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018, 124, 2115-2124.	4.1	79
22	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 405-412.	1.6	40
23	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	3.6	22
24	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
25	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1041-1053.	4.9	171
26	Apatersen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018, 118, 1434-1441.	6.4	34
27	Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2018, 39, 642-645.	1.3	33
28	Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4568-4568.	1.6	4
29	Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9513-9513.	1.6	6
30	EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS532-TPS532.	1.6	5
31	Outcomes in bone predominant (BP) urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 441-441.	1.6	0
32	Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-454.	1.6	9
33	Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. <i>Journal of Clinical Oncology</i> , 2018, 36, 109-109.	1.6	0
34	Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16523-e16523.	1.6	0
35	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	4.9	220
36	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. <i>JAMA Oncology</i> , 2017, 3, e172411.	7.1	750

#	ARTICLE	IF	CITATIONS
37	Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology, 2017, 35, 4525-4525.	1.6	30
38	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. Journal of Clinical Oncology, 2017, 35, 4534-4534.	1.6	2
39	Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI).. Journal of Clinical Oncology, 2017, 35, e16005-e16005.	1.6	1
40	A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3111-TPS3111.	1.6	5
41	Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2017, 35, 4548-4548.	1.6	0
42	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	4.9	93
43	Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. Urology, 2016, 90, 69-75.	1.0	18
44	Editorial Comment. Urology, 2016, 88, 132-133.	1.0	2
45	Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study. Translational Oncology, 2016, 9, 155-162.	3.7	94
46	Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Research, 2015, 75, 1356-1365.	0.9	63
47	Characteristics and Survival of Malignant Cardiac Tumors. Circulation, 2015, 132, 2395-2402.	1.6	117
48	Early Response Monitoring of Receptor Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma Using [F-18]Fluorothymidine-Positron Emission Tomography-Magnetic Resonance. Seminars in Roentgenology, 2014, 49, 238-241.	0.6	4
49	The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials, 2014, 35, 6595-6602.	11.4	121
50	Targeted nanotechnology for cancer imaging. Advanced Drug Delivery Reviews, 2014, 76, 79-97.	13.7	160
51	Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1124-1134.	3.3	51
52	Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery. Journal of Controlled Release, 2012, 164, 41-48.	9.9	75
53	Hodgkin's Lymphoma of the Breast. Journal of Clinical Oncology, 2010, 28, e11-e13.	1.6	15
54	Redefining hormone resistance in prostate cancer. Therapeutic Advances in Medical Oncology, 2010, 2, 107-123.	3.2	41

#	ARTICLE	IF	CITATIONS
55	TROG 96.01: TTF and PSAdt as surrogates for disease specific mortality. Update on Cancer Therapeutics, 2009, 3, 157-159.	0.4	0